


PRODUCT: CCT-137690

ALTERNATE NAMES: 3-[[4-[6-bromo-2-[4-(4-methylpiperazin-1-yl)phenyl]-1H-imidazo[4,5-b]pyridin-7-yl]piperazin-1-yl]methyl]-5-methyl-1,2-oxazole

CATALOG NUMBER: B1935-5,25

AMOUNT: 5 mg, 25 mg

STRUCTURE:

MOLECULAR FORMULA: C₂₆H₃₁BrN₈O

MOLECULAR WEIGHT: 551.48

CAS NUMBER: 1095382-05-0

APPEARANCE: Crystalline solid

SOLUBILITY: DMSO (~ 7 mg/ml)

PURITY: ≥98% by HPLC

STORAGE: Store at -20 °C. Protect from air and light

DESCRIPTION: CCT-137690 is a highly selective and orally bioavailable inhibitor of Aurora A, Aurora B and Aurora C with IC₅₀ of 15 nM, 25 nM and 19 nM, respectively. Displays anti-tumor activities both in vitro and in vivo. B

REFERENCES: Faisal, A., *et al.* (2011). *Molecular cancer therapeutics*, **10**, 2115-2123.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

RELATED PRODUCTS:

AT-9823 (Cat. No. 2432-5, 25)
Aurora Kinase B Inhibitor (Cat. No. 1583-5, 25)
AZD1480 (Cat. No. 2315-1, 5)
CCT-129202 (Cat. No. B1934-5,25)
CCT-137690 (Cat. No. B1935-5,25)
CP-690550 (Cat. No. 1622-5, 25)
Lestaurtinib (Cat. No. 1805-500, 1000)
MLN8237 (Cat. No. 2718-5,25)
LLL12 (Cat. No. 1792-5, 25)
MS-1020 (Cat. No. 1911-1)
PF-03814735 (Cat. No. B1257-1,5)
Reversine (Cat. No. 1851-1, 5)
Ruxolitinib, free base (Cat. No. 2139-5, 25)
Tozasertib (Cat. No. 1595-25, 100)
EZSolution™ Tozasertib (Cat. No. 1803-TC-S 7010 (Cat. No. B1203-5,25)
TG101348 (Cat. No. 2314-1, 5)
Tyrphostin AG 490 (Cat. No. 1570-5)
WHI-P131 (Cat. No. 1853-5, 25)
WP1066 (Cat. No. 1809-5, 25)

USAGE: **FOR RESEARCH USE ONLY! Not to be used in humans**